Study wrapper · #459
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis.
Editor's note
A preclinical study on MOTS-c and sperm production. The authors report that serum MOTS-c was lower in men with oligoasthenozoospermia and correlated with semen quality, then used a mouse mechanical-stress (microgravity) model to show spermatogenic impairment. Exogenous MOTS-c was associated with reduced oxidative stress and ferroptosis and better-preserved spermatogenesis, with SLC7A11 identified as a molecular target through loss- and gain-of-function experiments. These are preclinical findings plus a human correlation; human interventional data are needed before clinical conclusions can be drawn. Key caveats: the human component is observational and correlational (low MOTS-c associates with poorer semen quality, which does not establish direction or cause), and the therapeutic effect is demonstrated only in a mouse stress model. For a tracked peptide this is a mechanistically detailed but early signal for MOTS-c in male fertility, hypothesis-generating, not clinical evidence.
Plain-language abstract
This study explored whether MOTS-c, a small peptide made by mitochondria, plays a role in sperm production. Researchers first found that men with poor sperm quality had lower blood levels of MOTS-c, and that these levels tracked with semen quality measures. They then used mice, applying a stress model to damage sperm production, which reduced sperm numbers and disrupted the testes. When the mice were given MOTS-c, it lessened oxidative stress and a form of cell death called ferroptosis, helping preserve sperm production. The researchers identified a specific protein, SLC7A11, as the target through which MOTS-c acts. Because the human part of the study only measured associations, showing that lower MOTS-c goes along with poorer sperm quality rather than one causing the other, and the treatment effect was shown only in mice, these findings are early. The authors suggest MOTS-c could be worth studying as a possible approach for male infertility, but human trials would be needed.